ArriVent Financial Statements From 2010 to 2026

AVBP Stock   18.93  0.60  3.07%   
Analyzing historical trends in various income statement and balance sheet accounts from ArriVent BioPharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ArriVent BioPharma's valuation are summarized below:
Market Capitalization
806.2 M
Earnings Share
(4.15)
There are currently one hundred fundamental signals for ArriVent BioPharma Common that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate ArriVent BioPharma's prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction.
Check ArriVent BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ArriVent BioPharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.7 M, Selling General Administrative of 9.5 M or Selling And Marketing Expenses of 603.2 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.38. ArriVent financial statements analysis is a perfect complement when working with ArriVent BioPharma Valuation or Volatility modules.
  
Build AI portfolio with ArriVent Stock
Check out the analysis of ArriVent BioPharma Correlation against competitors.

ArriVent BioPharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets182.6 M316.2 M109.9 M
Slightly volatile
Other Current Liabilities16.1 M15.3 M5.1 M
Slightly volatile
Total Current Liabilities10.7 M19.9 M6.2 M
Slightly volatile
Total Stockholder Equity171.8 M296.3 M103.7 M
Slightly volatile
Accounts Payable3.2 M4.3 M1.5 M
Slightly volatile
Cash117 M85.4 M63.2 M
Slightly volatile
Non Current Assets Total57.9 M55.2 M12.5 M
Slightly volatile
Non Currrent Assets Other137.7 K144.9 K259 K
Pretty Stable
Other Assets0.80.90.9824
Slightly volatile
Cash And Short Term Investments156.7 M251.7 M92.4 M
Slightly volatile
Net Receivables553 K575 K361.1 K
Slightly volatile
Common Stock Shares Outstanding27 M36.2 M12.1 M
Slightly volatile
Liabilities And Stockholders Equity182.6 M316.2 M109.9 M
Slightly volatile
Other Current Assets8.4 M6.9 M7.2 M
Slightly volatile
Other Stockholder Equity599.2 M570.6 M129.6 M
Slightly volatile
Total Liabilities10.8 M19.9 M6.2 M
Slightly volatile
Total Current Assets168.4 M261 M99.9 M
Slightly volatile
Net Working Capital157.7 M241.2 M93.7 M
Slightly volatile
Common Stock2.9 K2.7 K3.7 K
Slightly volatile
Short and Long Term Debt Total231.7 K202.4 K163 K
Slightly volatile
Short Term Debt157.7 K186.3 K137.9 K
Slightly volatile

ArriVent BioPharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization26.7 M42.4 M20.3 M
Slightly volatile
Selling General Administrative9.5 M17.6 M6.3 M
Slightly volatile
Selling And Marketing Expenses603.2 K678.6 K740.7 K
Slightly volatile
Other Operating Expenses59 M108.5 M33.1 M
Slightly volatile
Research Development49.7 M90.9 M27.3 M
Slightly volatile
Total Operating Expenses59 M108.5 M33.1 M
Slightly volatile

ArriVent BioPharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.9 M3.7 M943 K
Slightly volatile
Other Cashflows From Financing Activities539.5 K567.9 K90.2 M
Slightly volatile
Total Cash From Financing Activities134.5 M214.6 M113.1 M
Slightly volatile
End Period Cash Flow117 M85.4 M63.2 M
Slightly volatile
Begin Period Cash Flow128.7 M172.9 M71.4 M
Slightly volatile
Issuance Of Capital Stock146.9 M213.8 M165.5 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
PTB Ratio2.382.931.4151
Slightly volatile
Book Value Per Share13.879.4225.241
Slightly volatile
PB Ratio2.382.931.4151
Slightly volatile
Cash Per Share12.588.022.8067
Slightly volatile
Income Quality0.620.790.4233
Slightly volatile
Net Debt To EBITDA1.011.061.0644
Slightly volatile
Current Ratio19.915.1121.604
Slightly volatile
Tangible Book Value Per Share13.879.4225.241
Slightly volatile
Shareholders Equity Per Share13.879.4225.241
Slightly volatile
Debt To Equity0.00138.0E-49.0E-4
Slightly volatile
Graham Net Net11.927.3821.7631
Slightly volatile
Interest Debt Per Share0.00520.0050.0047
Slightly volatile
Debt To Assets0.00127.0E-48.0E-4
Slightly volatile
Price Book Value Ratio2.382.931.4151
Slightly volatile
Ebt Per Ebit0.930.984.4609
Slightly volatile
Effective Tax Rate0.180.20.2206
Slightly volatile
Company Equity Multiplier0.850.961.0313
Slightly volatile
Total Debt To Capitalization0.00138.0E-49.0E-4
Slightly volatile
Debt Equity Ratio0.00138.0E-49.0E-4
Slightly volatile
Quick Ratio19.915.1121.604
Slightly volatile
Cash Ratio4.74.9517.2061
Slightly volatile
Price To Book Ratio2.382.931.4151
Slightly volatile
Debt Ratio0.00127.0E-48.0E-4
Slightly volatile
Price Fair Value2.382.931.4151
Slightly volatile

ArriVent BioPharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap670.7 M754.5 M823.5 M
Slightly volatile
Enterprise Value611.4 M687.8 M750.7 M
Slightly volatile

ArriVent Fundamental Market Drivers

About ArriVent BioPharma Financial Statements

ArriVent BioPharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although ArriVent BioPharma investors may analyze each financial statement separately, they are all interrelated. The changes in ArriVent BioPharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on ArriVent BioPharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue(0.90)(0.94)

Pair Trading with ArriVent BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving against ArriVent Stock

  0.64MSFT MicrosoftPairCorr
  0.57PG Procter GamblePairCorr
  0.52HD Home DepotPairCorr
  0.5CVX Chevron CorpPairCorr
  0.5GE GE AerospacePairCorr
The ability to find closely correlated positions to ArriVent BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma Common to buy it.
The correlation of ArriVent BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for ArriVent Stock Analysis

When running ArriVent BioPharma's price analysis, check to measure ArriVent BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma is operating at the current time. Most of ArriVent BioPharma's value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma's price. Additionally, you may evaluate how the addition of ArriVent BioPharma to your portfolios can decrease your overall portfolio volatility.